Symposium 3: Fasting plasma glucose, HbA1c or oral glucose tolerance test: should we use the three tests to evaluate the patient?
The objective of the presentation will be to answer , based on some evidences,referred to the eventual additive contributions of the three tests with Progession to Diabetes (PDMT2) and/or exposure to Cardiovascular Risk (CVR) or Chronic Renal Disease (CRD) and how we can use them from a clinical per...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Sello Editorial Lugones
2022-09-01
|
| Series: | Revista de la Sociedad Argentina de Diabetes |
| Subjects: | |
| Online Access: | https://revistasad.com/index.php/diabetes/article/view/553 |
| Summary: | The objective of the presentation will be to answer , based on some evidences,referred to the eventual additive contributions of the three tests with Progession to Diabetes (PDMT2) and/or exposure to Cardiovascular Risk (CVR) or Chronic Renal Disease (CRD) and how we can use them from a clinical perspective.
In prediabetes definition there are no discrepancias regarding to Impaired Glucose Tolerance (IGT), but they are obvious regarding Impaired Fasting Glucose (IFG) = American Diabetes Association criteria : 100-125 mg/dl an World Health Organization : 110-125 mg/dl. There no agreement also for “intermediate” HbA1c cutoffs = (HbA1c(5.7-6.4%)) for American Diabetes Association and (HbA1c(6.1-6.4%)) in UK (NICE). These divergences have different risk of progression and also the pathophysiological contributions of each of the evaluations could be complementary. |
|---|---|
| ISSN: | 0325-5247 2346-9420 |